KIAA1239 Inhibitors
KIAA1239 inhibitors represent a class of chemical compounds specifically designed to impede the activity of the KIAA1239 protein, which is encoded by a gene implicated in various cellular processes. These inhibitors work by targeting the biochemical pathways that KIAA1239 is involved in, rather than affecting the protein's transcription or translation directly. Each inhibitor within this class has a unique mechanism of action, ensuring specificity in their interaction with KIAA1239 or its related signaling pathways. For instance, some compounds might directly bind to KIAA1239, altering its conformation and thus inhibiting its function, while others may interfere with upstream regulators or downstream effectors associated with the protein's activity. The specificity of KIAA1239 inhibitors ensures that their effects are localized to the processes in which KIAA1239 is a critical component, such as signal transduction pathways or cellular transport mechanisms, without significantly impacting unrelated biological systems.
The development of KIAA1239 inhibitors is guided by a profound understanding of the protein's role in cellular biology. The structural diversity of these inhibitors reflects the complexity of the protein's interactions within the cell. Some inhibitors might resemble substrate analogs, competitively inhibiting the binding of natural substrates to KIAA1239. Others may act allosterically, binding to a site distinct from the active site, leading to a functional change in the protein's activity. Additionally, certain inhibitors could deter the protein's function by influencing post-translational modifications that are crucial for KIAA1239's activity. A hallmark of these inhibitors is their ability to consistently produce a state of decreased activity of KIAA1239 in a controlled and predictable manner. This precise inhibition is crucial for studying the protein's role in the complex web of cellular signaling and for exploring the molecular intricacies of the pathways KIAA1239 is involved in. Through these mechanisms, KIAA1239 inhibitors provide valuable tools for dissecting the protein's function and understanding its contribution to cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits mTOR (mechanistic target of rapamycin), which is crucial for protein synthesis. Inhibition of mTOR leads to reduced protein translation and can thereby decrease the functional activity of KIAA1239 if its expression relies on mTOR-mediated pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is part of the PI3K/AKT/mTOR signaling pathway. By inhibiting PI3K, it prevents the activation of AKT, thereby reducing the phosphorylation and activity of downstream targets, including mTOR. This can result in lower expression or activity of KIAA1239 if it is downstream of this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts by covalently bonding to the catalytic site of PI3K, leading to its inhibition. This results in the blockade of the PI3K/AKT/mTOR signaling cascade, which can indirectly inhibit the synthesis or function of KIAA1239 by limiting upstream signaling events. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of ERK in the MAPK/ERK pathway. By inhibiting MEK, U0126 prevents the activation of ERK and the subsequent transcriptional regulation of genes. If KIAA1239 is regulated by ERK-mediated transcription, its expression would be reduced. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that works by binding to the inactive forms of MEK1/2, preventing their activation by upstream kinases. This inhibition can decrease ERK activation and thus may indirectly reduce the expression or activity levels of KIAA1239. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which affects transcription factors and cellular functions. By inhibiting JNK, SP600125 can influence the transcription of certain genes. If KIAA1239 is one such gene, its expression or activity would be reduced by this chemical. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. Inhibition of p38 kinase can affect the stress response and cytokine production in cells. If the activity or stability of KIAA1239 is influenced by p38 MAPK-regulated pathways, then SB203580 could decrease its functional activity indirectly. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor with broad specificity. By inhibiting Src family kinases and Bcr-Abl, it impacts various signaling pathways involved in cell growth and survival. If these pathways contribute to the regulation or activity of KIAA1239, dasatinib would result in its decreased function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is an inhibitor of Bcr-Abl and c-Kit, which participate in cell proliferation and survival pathways. If KIAA1239 is associated with these pathways, imatinib could indirectly reduce its activity by blocking the signaling required for its function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are essential for cell cycle progression. By arresting the cell cycle, palbociclib can lead to reduced protein synthesis, potentially decreasing the functional activity of KIAA1239 if it is cell-cycle dependent. | ||||||